Clinical trial NCT00583167: CNS (Central Nervous System) Viral Dynamics and Cellular Immunity During AIDS
Official title: CNS Viral Dynamics and Cellular Immunity During AIDS
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HIV Infections
Keywords: HIV
AIDS
CNS
brain
affects
Lead sponsor: Vanderbilt University
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2007-12-31
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA \>20,000 copies/mL. Individuals with past ART experience must have the ability to construct an ART regimen predicted to completely suppress plasma HIV-1 RNA, based on results of viral susceptibility testing that is done as a routine part of clinical practice.

Brief summary: Understanding whether or not viral replication occurs in the brain during chronic untreated HIV-1 infection is of undeniable importance, and has implications for treatment and research priorities. Evidence suggests that viral replication in the CNS occurs at the extremes of HIV-1 disease. Brain involvement has been reported during acute infection, and there is convincing evidence of CNS viral replication during HIV-associated dementia (HAD) and advanced AIDS. Some human and primate data suggest that viral RNA and proteins may be absent from brains of some individuals with chronic untreated HIV-1 infection despite abundant proviral DNA. However, the extent of viral replication in the brain is not known for most of the 42 million people worldwide living with untreated HIV-1 infection.

Why is viral replication in the brain such a pivotal issue? Microglial cells and macrophages are primary targets for intrathecal HIV-1 replication, and this can promote neuronal injury through direct effects of gp120 and tat, and indirect induction of toxic mediators. Low-grade injury over years or decades would likely be deleterious, particularly as the population ages. Because treatment guidelines allow systemic HIV-1 replication to continue until CD4+ T cell counts decline considerably, antiretroviral therapy (ART) is not recommended for many persons living with HIV. Demonstrating replication in the brain during chronic HIV-1 infection may affect treatment strategies and encourage investigation.

Identifying factors that modulate intrathecal viral replication is equally important. Anti-HIV-1 cytotoxic T lymphocytes (CTL) partially control systemic viral replication and delay disease progression. Although available data has been provocative, the role of anti-HIV CTL in the CNS has received little attention. To fill this gap we will examine relationships between intrathecal viral replication, CTL responses, and glial activation/proliferation during HIV-1 infection. These studies will be relevant not only to AIDS but to other inflammatory diseases of the CNS as well.


Eligibility criteria: Inclusion Criteria:

* (All subjects in Groups A1, A2 and B):
* At least 18 years of age.
* No more than one month of ART in the past.
* No ART in the previous 3 months.
* Platelet count \>100,000 cells/mm3 on most recent determination within 60 days prior to first study lumbar puncture.
* Normal prothrombin time (PT) and partial thromboplastin time (PTT) on most recent determination within 60 days prior to first study lumbar puncture.
* Among individuals with past ART experience, the ability to construct an ART regimen predicted to completely suppress plasma HIV-1 RNA, based on results of viral susceptibility testing that is done as a routine part of clinical practice.
* Plasma HIV-1 RNA \>20,000 copies/mL.
* Additional Inclusion Criteria for Groups A1 and A2.
* Group A1:
* CD4+ T cell count \>200 cells/mm3.
* CSF HIV-1 RNA \>2,000 copies/mL on screening lumbar puncture.
* No history of significant allergy to beta lactam antibiotics, including penicillins and cephalosporins.
* No history of allergy to vancomycin.
* Group A2:
* CD4+ T cell count \<200 cells/mm3.
* CSF HIV-1 RNA \>2,000 copies/mL on screening lumbar puncture.
* No history of significant allergy to beta lactam antibiotics, including penicillins and cephalosporins.
* No history of allergy to vancomycin.

Exclusion Criteria:

* Evidence of CNS opportunistic infections or space occupying lesion.
* History of significant CNS disorder unrelated to HIV infection such as trauma, congenital malformations or genetic disorders.
* History of seizures.
* As determined by the investigator, a significant active or previous history of cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, or endocrine disease(s) that would interfere with study participation.
* Evidence or suspicion of vascular or Alzheimer's type dementias.
* Evidence or suspicion of Parkinson's disease.
* History of allergy to lidocaine.
* Implanted metal objects that make MRI contraindicated. This may require consultation with colleagues in the Vanderbilt Dept. of Radiology.
* Women who are pregnant or breastfeeding.
* Women with a positive pregnancy test on enrollment or prior to study drug administration.
* Women of childbearing potential (WOCBP) who are unwilling or unable to use an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized.
* Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.

Primary outcomes:
measure: To characterize intrathecal viral replication during chronic untreated HIV-1 infection, and to assess how intrathecal viral replication relates to stage of HIV-1 disease.
timeFrame: end of study
measure: To measure intrathecal and systemic cellular immune responses against HIV-1 and to assess how these responses relate to intrathecal viral replication.
timeFrame: end of study
measure: To correlate intrathecal viral replication and anti-HIV CTL responses with the degree of glial activation/proliferation and neuronal dropout in the brain.
timeFrame: end of study
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt AIDS Clinical Trials Center
state: Tennessee
Study officials:
affiliation: Vanderbilt University
name: David W. Haas, MD
role: PRINCIPAL_INVESTIGATOR
References: